Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of CancerElise A. Olsen, Eric C. Vonderheid, Rein Willemze et al.|Journal of Clinical Oncology|2011Cited by 657
Enabling Technologies for Personalized and Precision MedicineDean Ho, Ali Zarrinpar, Stephen R. Quake et al.|Trends in biotechnology|2020Cited by 483
Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b studyJohn F. Seymour, Andrew W. Roberts, Shuo Ma et al.|The Lancet Oncology|2017Cited by 327
Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell TransplantationAlex F. Herrera, Philippe Armand, Matthew Mei et al.|Journal of Clinical Oncology|2016Cited by 187
Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapyJeremy S. Abramson, Andrew M. Evens, Tatyana Feldman et al.|Annals of Oncology|2014Cited by 138